Countries considering whether to introduce new health interventions rely on a range of information, including estimates of public health impact and cost-effectiveness. To assist countries in decisions on whether to include the RTS,S/AS01 malaria vaccine in their routine immunization programs, PATH is overseeing work, conducted by partner research institutions, to assess the cost effectiveness and public health impact of the malaria vaccine.

Data gathered in the three countries participating in the pilot program—Ghana, Kenya, and Malawi—were combined with Phase 3 data, and previously validated malaria transmission models were used to update estimates of public health impact and cost-effectiveness.